Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.

Trial Profile

Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2013

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; Zanolimumab
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Genmab
  • Most Recent Events

    • 08 May 2009 Official Title amended, actual initiation date (May 2007) added, patient number (5) added, Genmab added as trial sponsor as reported by ClinicalTrials.gov.
    • 08 May 2009 CHOP identified as a component of treatment as reported by ClinicalTrials.gov.
    • 08 May 2009 Status changed from planning to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top